|
Oct 17
|
Exscientia advances two additional discovery programs with Sanofi
|
|
Oct 16
|
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
|
|
Oct 9
|
Exscientia to Present New Preclinical Data for AI-designed LSD1 and MALT1 Inhibitors at ENA 2024
|
|
Oct 4
|
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
|
|
Jul 31
|
Why Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket?
|
|
Jul 19
|
Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial
|
|
Jul 18
|
Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data Readout
|
|
May 14
|
Exscientia to Report First Quarter 2024 Financial Results on May 21, 2024
|
|
Mar 21
|
Exscientia Business and Financial Update for the Full Year 2023
|
|
Mar 19
|
Exscientia plc's (NASDAQ:EXAI) market cap touched US$797m last week, benefiting both individual investors who own 48% as well as institutions
|
|
Mar 14
|
Exscientia to Report Full Year 2023 Financial Results on March 21, 2024
|
|
Mar 4
|
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
|
|
Feb 13
|
Oxford drug company sacks chief executive over ‘inappropriate’ relationships with staff
|
|
Jan 2
|
Professor Andrew L. Hopkins appointed Commander of the Order of the British Empire (CBE)
|
|
Dec 30
|
Ozempic drugmaker to open AI research hub in King’s Cross
|
|
Dec 21
|
Wall Street Analysts See a 67.76% Upside in Exscientia PLC Sponsored ADR (EXAI): Can the Stock Really Move This High?
|
|
Dec 21
|
Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme
|
|
Dec 7
|
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now
|
|
Dec 6
|
We Think Exscientia (NASDAQ:EXAI) Needs To Drive Business Growth Carefully
|
|
Dec 5
|
Exscientia Receives Open Philanthropy Grant to Explore New Therapeutic Approach for Pandemic Influenza
|